A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Inclusion criteria:

• Adult patients (≥ 18 years).

• Presenting with primary immunodeficiency.

• Having received subcutaneous injections of immunoglobulin at home using an automaticpump or syringe for at least 1 month at the time of inclusion.

• For whom the investigator decides to maintain immunoglobulin replacement therapy withsubcutaneous injections of Gammanorm® 165 mg/mL at home.

• Freely given written informed consent from patient.

• Women of childbearing potential must have a negative result on a pregnancy test (humanchorionic gonadotropine [HCG]-based assay) and need to practice contraception using amethod of proven reliability for the duration of the study.

Exclusion Criteria:

• Participating in another interventional clinical study and receiving investigationalmedicinal product within three months before study entry.